Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
What the buyer wrote
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Type
- goods
- Where
- in Wales
- Kind of work
- Health and social care
Who the buyer named
The buyer published a contact address on this notice.